Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

bobbseytwins2001

erippetoe

JJINV

From: idahoranch1	12/13/2019 12:26:53 PM
	3 Recommendations Read Replies (2) of 63310

“In a stunning reversal, the Food and Drug Administration approved Sarepta Therapeutics' ( SRPT) previously rejected Duchenne muscular dystrophy drug — sending SRPT stock rocketing on Friday.” Another sign that FDA is leaning more towards patients than they have been.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next